Published in TB and Outbreaks Week, March 4th, 2003
This new patent provides protection for a series of compounds discovered at the UAB-CBSE and licensed exclusively to VDDI by the UABRF. The compounds interact with a unique, and to date unexploited, microbial target (NAD...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.